337 related articles for article (PubMed ID: 26209894)
1. Eosinophilia in Hematologic Disorders.
Falchi L; Verstovsek S
Immunol Allergy Clin North Am; 2015 Aug; 35(3):439-52. PubMed ID: 26209894
[TBL] [Abstract][Full Text] [Related]
2. Eosinophilic myeloid disorders: new classification and novel therapeutic strategies.
Gotlib J
Curr Opin Hematol; 2010 Mar; 17(2):117-24. PubMed ID: 20071982
[TBL] [Abstract][Full Text] [Related]
3. [Hematological disorders and hypereosinophilias].
Malfuson JV; Fagot T; Konopacki J; Mangouka L; Souleau B; de Revel T
Rev Med Interne; 2009 Apr; 30(4):322-30. PubMed ID: 19201511
[TBL] [Abstract][Full Text] [Related]
4. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2015 Nov; 90(11):1077-89. PubMed ID: 26486351
[TBL] [Abstract][Full Text] [Related]
5. A novel acquired cryptic three-way translocation t(2;11;5)(p21.3;q13.5;q23.2) with a submicroscopic deletion at 11p14.3 in an adult with hypereosinophilic syndrome.
Kjeldsen E
Exp Mol Pathol; 2015 Aug; 99(1):50-5. PubMed ID: 25962659
[TBL] [Abstract][Full Text] [Related]
6. Molecular classification and pathogenesis of eosinophilic disorders: 2005 update.
Gotlib J
Acta Haematol; 2005; 114(1):7-25. PubMed ID: 15995322
[TBL] [Abstract][Full Text] [Related]
7. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.
Tefferi A; Gotlib J; Pardanani A
Mayo Clin Proc; 2010 Feb; 85(2):158-64. PubMed ID: 20053713
[TBL] [Abstract][Full Text] [Related]
8. Eosinophilic myeloid disorders.
Noel P
Semin Hematol; 2012 Apr; 49(2):120-7. PubMed ID: 22449622
[TBL] [Abstract][Full Text] [Related]
9. Myeloid neoplasms with eosinophilia.
Reiter A; Gotlib J
Blood; 2017 Feb; 129(6):704-714. PubMed ID: 28028030
[TBL] [Abstract][Full Text] [Related]
10. World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2011 Aug; 86(8):677-88. PubMed ID: 21761433
[TBL] [Abstract][Full Text] [Related]
11. Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review.
Savage N; George TI; Gotlib J
Int J Lab Hematol; 2013 Oct; 35(5):491-500. PubMed ID: 23489324
[TBL] [Abstract][Full Text] [Related]
12. Imatinib for the treatment of hypereosinophilic syndromes.
Helbig G
Expert Rev Clin Immunol; 2018 Feb; 14(2):163-170. PubMed ID: 29303368
[TBL] [Abstract][Full Text] [Related]
13. [Characteristics of cytogenetics and molecular biology in patients with eosinophilia].
Qu SQ; Ai XF; Li CW; Li QH; Xu ZF; Qin TJ; Zhang Y; Xiao ZJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1216-20. PubMed ID: 23114151
[TBL] [Abstract][Full Text] [Related]
14. Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders.
Pardanani A; Tefferi A
Leuk Res; 2004 May; 28 Suppl 1():S47-52. PubMed ID: 15036941
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive genomic profiling identifies a novel TNKS2-PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy.
Chalmers ZR; Ali SM; Ohgami RS; Campregher PV; Frampton GM; Yelensky R; Elvin JA; Palma NA; Erlich R; Vergilio JA; Chmielecki J; Ross JS; Stephens PJ; Hermann R; Miller VA; Miles CR
Blood Cancer J; 2015 Feb; 5(2):e278. PubMed ID: 25658984
[No Abstract] [Full Text] [Related]
16. Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature.
Müller AM; Martens UM; Hofmann SC; Bruckner-Tuderman L; Mertelsmann R; Lübbert M
Ann Hematol; 2006 Jan; 85(1):1-16. PubMed ID: 16136348
[TBL] [Abstract][Full Text] [Related]
17. Modern diagnosis and treatment of primary eosinophilia.
Tefferi A
Acta Haematol; 2005; 114(1):52-60. PubMed ID: 15995325
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders.
Cross NC; Reiter A
Acta Haematol; 2008; 119(4):199-206. PubMed ID: 18566537
[TBL] [Abstract][Full Text] [Related]
19. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.
Patterer V; Schnittger S; Kern W; Haferlach T; Haferlach C
Ann Hematol; 2013 Jun; 92(6):759-69. PubMed ID: 23400675
[TBL] [Abstract][Full Text] [Related]
20. [Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1].
Fan XS; Wang SA
Zhonghua Bing Li Xue Za Zhi; 2012 Nov; 41(11):779-83. PubMed ID: 23302345
[No Abstract] [Full Text] [Related]
[Next] [New Search]
